Literature DB >> 31704880

Immune-Focusing Properties of Virus-like Particles Improve Protective IgA Responses.

Taishi Onodera1, Kana Hashi1, Rajni Kant Shukla1, Motohiro Miki2,3, Reiko Takai-Todaka2, Akira Fujimoto2, Masayuki Kuraoka4, Tatsuya Miyoshi5, Kazuo Kobayashi6, Hideki Hasegawa7, Manabu Ato1, Garnett Kelsoe4, Kazuhiko Katayama2, Yoshimasa Takahashi8.   

Abstract

Virus-like particles (VLPs) provide a well-established vaccine platform; however, the immunogenic properties acquired by VLP structure remain poorly understood. In this study, we showed that systemic vaccination with norovirus VLP recalls human IgA responses at higher magnitudes than IgG responses under a humanized mouse model that was established by introducing human PBMCs in severely immunodeficient mice. The recall responses elicited by VLP vaccines depended on VLP structure and the disruption of VLP attenuated recall responses, with a more profound reduction being observed in IgA responses. The IgA-focusing property was also conserved in a murine norovirus-primed model under which murine IgA responses were recalled in a manner dependent on VLP structure. Importantly, the VLP-driven IgA response preferentially targeted virus-neutralizing epitopes located in the receptor-binding domain. Consequently, VLP-driven IgA responses were qualitatively superior to IgG responses in terms of the virus-neutralizing activity in vitro. Furthermore, the IgA in mucosa obtained remarkable protective function toward orally administrated virus in vivo. Thus, our results indicate the immune-focusing properties of the VLP vaccine that improve the quality/quantity of mucosal IgA responses, a finding with important implications for developing mucosal vaccines.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31704880      PMCID: PMC6900486          DOI: 10.4049/jimmunol.1900481

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults.

Authors:  John J Treanor; Robert L Atmar; Sharon E Frey; Robert Gormley; Wilbur H Chen; Jennifer Ferreira; Robert Goodwin; Astrid Borkowski; Ralf Clemens; Paul M Mendelman
Journal:  J Infect Dis       Date:  2014-06-20       Impact factor: 5.226

Review 2.  Prospects and Challenges in the Development of a Norovirus Vaccine.

Authors:  Nicolas W Cortes-Penfield; Sasirekha Ramani; Mary K Estes; Robert L Atmar
Journal:  Clin Ther       Date:  2017-07-26       Impact factor: 3.393

3.  Whole-Virion Influenza Vaccine Recalls an Early Burst of High-Affinity Memory B Cell Response through TLR Signaling.

Authors:  Taishi Onodera; Akira Hosono; Takato Odagiri; Masato Tashiro; Shuichi Kaminogawa; Yoshinobu Okuno; Tomohiro Kurosaki; Manabu Ato; Kazuo Kobayashi; Yoshimasa Takahashi
Journal:  J Immunol       Date:  2016-04-06       Impact factor: 5.422

4.  Effects of disinfectants against norovirus virus-like particles predict norovirus inactivation.

Authors:  Jun Sato; Motohiro Miki; Hiromi Kubota; Jun Hitomi; Hajime Tokuda; Reiko Todaka-Takai; Kazuhiko Katayama
Journal:  Microbiol Immunol       Date:  2016-09       Impact factor: 1.955

5.  Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation.

Authors:  Andrea Jegerlehner; Tazio Storni; Gerd Lipowsky; Markus Schmid; Paul Pumpens; Martin F Bachmann
Journal:  Eur J Immunol       Date:  2002-11       Impact factor: 5.532

6.  Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.

Authors:  David I Bernstein; Robert L Atmar; G Marshall Lyon; John J Treanor; Wilbur H Chen; Xi Jiang; Jan Vinjé; Nicole Gregoricus; Robert W Frenck; Christine L Moe; Mohamed S Al-Ibrahim; Jill Barrett; Jennifer Ferreira; Mary K Estes; David Y Graham; Robert Goodwin; Astrid Borkowski; Ralf Clemens; Paul M Mendelman
Journal:  J Infect Dis       Date:  2014-09-09       Impact factor: 5.226

7.  Immunogenetic mechanisms driving norovirus GII.4 antigenic variation.

Authors:  Lisa C Lindesmith; Martina Beltramello; Eric F Donaldson; Davide Corti; Jesica Swanstrom; Kari Debbink; Antonio Lanzavecchia; Ralph S Baric
Journal:  PLoS Pathog       Date:  2012-05-17       Impact factor: 6.823

Review 8.  Systematic literature review of role of noroviruses in sporadic gastroenteritis.

Authors:  Manish M Patel; Marc-Alain Widdowson; Roger I Glass; Kenichiro Akazawa; Jan Vinjé; Umesh D Parashar
Journal:  Emerg Infect Dis       Date:  2008-08       Impact factor: 6.883

9.  Memory B Cells that Cross-React with Group 1 and Group 2 Influenza A Viruses Are Abundant in Adult Human Repertoires.

Authors:  Kevin R McCarthy; Akiko Watanabe; Masayuki Kuraoka; Khoi T Do; Charles E McGee; Gregory D Sempowski; Thomas B Kepler; Aaron G Schmidt; Garnett Kelsoe; Stephen C Harrison
Journal:  Immunity       Date:  2018-01-16       Impact factor: 43.474

10.  Distinct germinal center selection at local sites shapes memory B cell response to viral escape.

Authors:  Yu Adachi; Taishi Onodera; Yuki Yamada; Rina Daio; Makoto Tsuiji; Takeshi Inoue; Kazuo Kobayashi; Tomohiro Kurosaki; Manabu Ato; Yoshimasa Takahashi
Journal:  J Exp Med       Date:  2015-08-31       Impact factor: 14.307

View more
  3 in total

1.  Hide and seek: interplay between influenza viruses and B cells.

Authors:  Masayuki Kuraoka; Yu Adachi; Yoshimasa Takahashi
Journal:  Int Immunol       Date:  2020-09-08       Impact factor: 4.823

2.  IgA Responses Following Recurrent Influenza Virus Vaccination.

Authors:  Rodrigo B Abreu; Emily F Clutter; Sara Attari; Giuseppe A Sautto; Ted M Ross
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

Review 3.  Understanding the relationship between norovirus diversity and immunity.

Authors:  Lauren A Ford-Siltz; Kentaro Tohma; Gabriel I Parra
Journal:  Gut Microbes       Date:  2021 Jan-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.